Abstract a bone metabolism regulator that is expressed by osteocytes in normal adult bone. Here, we used an immunohistochemical approach to study whether Mepe has a role in murine long bone development and regeneration. Our data showed that Mepe protein was produced by osteoblasts and osteocytes during skeletogenesis, as early as 2 days postnatal. During the healing of non-stabilized tibial fractures, which occurs through endochondral ossification, Mepe expression was first detected in fibroblast-like cells within the callus by 6 days postfracture. By 10 and 14 days postfracture (the hard callus phase of repair), Mepe was expressed within late hypertrophic chondrocytes and osteocytes in the regenerating tissues. Mepe became externalized in osteocyte lacunae during this period. By 28 days postfracture (the remodeling phase of repair), Mepe continued to be robustly expressed in osteocytes of the regenerating bone. We compared the Mepe expression profile with that of alkaline phosphatase, a marker of bone mineralization. We found that both Mepe and alkaline phosphatase increased during the hard callus phase of repair. In the remodeling phase of repair, Mepe expression levels remained high while alkaline phosphatase activity decreased. We also examined Mepe expression during cortical bone defect healing, which occurs through intramembranous ossification. Mepe immunostaining was found within fibroblast-like cells, osteoblasts, and osteocytes in the regenerating bone, through 5 to 21 days postsurgery. Thus, Mepe appears to play a role in both long bone regeneration and the latter stages of skeletogenesis.
Introduction
Matrix extracellular phosphoglycoprotein (Mepe, also called OF45) is a novel gene initially identified in oncogenic hypophosphatemic osteomalacia (OHO), a rare syndrome of rickets/osteomalacia and hypophosphatemia associated with a coexisting tumor (Argiro et al. 2001; Nelson et al. 1997; Petersen et al. 2000; Rowe et al. 2000) . Mepe protein shares structural similarity with other bone and dentin mineral matrix phosphoglycoproteins (Rowe et al. 2000) and, like these other molecules, is expressed within osteocytes of adult bone (Petersen et al. 2000; Rowe et al. 2000) . In vitro, Mepe is expressed by differentiated osteoblasts and its expression is markedly increased during osteoblast-mediated matrix mineralization (Argiro et al. 2001; Petersen et al. 2000) . Mepe / knockout mice have a phenotype of increased bone mass in the femur (Gowen et al. 2003) . Bone marrow cultures from Mepe / mutant mice show increased osteoblast number and osteoblast activity (Gowen et al. 2003) . Collectively, these studies indicate that Mepe is a bone metabolism regulator, and that its primary function might be inhibiting bone formation.
In past decades, research on bone biology has not only advanced our knowledge of fetal skeletogenesis, but it has also provided clues as to how we may augment or stimulate bone regeneration in cases of delayed skeletal repair. For example, bone morphogenetic proteins, transforming growth factors, and fibroblast growth factors may enhance bone formation (Lieberman et al. 2002; Sandhu and Khan 2003; Valentin-Opran et al. 2002) . Our interest in Mepe arose from its role as a bone metabolism regulator and as a potential novel target for enhancing fracture healing. As a first step toward testing this potential, we used an immunohistochemical approach to study Mepe protein expression during murine long bone skeletogenesis, during tibia fracture and cortical bone defect healing.
Generation of non-stabilized fractures
Raven wild-type mice were used in this study. For all surgical procedures, 6-month-old, 30-to 35-g male mice were used. The surgical procedure followed established protocols approved by the UCSF Committee on Animal Research. Mice were given an intraperitoneal injection of 2% Avertin, 0.015 ml/g body weight, to provide approximately 15-20 min of deep anesthesia. Closed nonstabilized transverse mid-diaphyseal fractures of the tibia were created with a three-point bending apparatus as described previously (Bonnarens and Einhorn 1984; Thompson et al. 2002) . Radiographs were taken immediately after fracture to confirm the extent of fracture. After recovery, animals were allowed to ambulate ad libitum and analgesics were provided for the first 48 h (Buprenorphine, ZT Sigma, St. Louis, MO). Mice were carefully monitored at frequent intervals for any signs of infection and discomfort. Mice were killed by cervical dislocation after Avertin anesthesia at 3, 6, 10, 14, and 28 days postfracture. Fractured tibias were harvested for histological and Mepe immunohistochemical study.
Generation of cortical bone defect
Raven wild-type mice were used as in the fracture study. Under Avertin-induced deep anesthesia, an anterior longitudinal incision was made over the proximal tibia, and a 1.0-mm-diameter hole was created in the diaphysis, proximal to the tibia tubercle, using a dental drill. Drilling was halted as soon as the medullary cavity was accessed, thereby leaving the far cortex intact. After recovery, animals were allowed to ambulate ad libitum. Mice were killed and the tibias were harvested at 3, 6, 10, 14, and 28 days postsurgery.
Tissue preparation
All skeletal tissues were collected and fixed at 4C in 4% PFA overnight. Tissues were decalcified at 4C in 19% EDTA, pH 7.4, for 2-14 days. All skeletal tissues were prepared for analyses by dehydration in a graded ethanol series and embedded in paraffin (Albrecht et al. 1997) . Seven-micron sections were prepared from postnatal tissues, and 10-mm sections were prepared from adult skeletal tissues.
Histological staining
For histological study, safranin O/fast green staining was used to show the cartilage formation and its replacement by new bone during skeletogenesis and non-stabilized fracture healing. The cartilage is stained a red color, while the bone and soft tissue is green in color.
To show new bone formation during cortical bone defect healing, trichrome staining was performed on the slides adjacent to that used in Mepe immunostaining. The bone was stained blue and soft tissue red.
Alkaline phosphatase staining
To visualize bone mineralization during non-stabilized fracture, alkaline phosphatase staining was performed on slides adjacent to those used for immunostaining. Slides were dewaxed, incubated in alkaline phosphatase buffer (100 mM TRIS pH 9.5, 50 mM MgCl 2 , 10 mM NaCl, and 0.1% Tween 20, dH 2 0) at 4C for 24 h, then in BM-purple solution (Roche Diagnostic, Indianapolis, IN) at 4C overnight, and lightly counterstained with eosin. A dark blue color reaction indicated alkaline phosphatase activity.
Mepe immunostaining
The primary antibody (Acologix, Emeryville, CA; PAB-1274) used was a rabbit anti-mouse polyclonal antibody generated against a peptide segment of mouse Mepe. Tissue sections were dewaxed and rehydrated from a graded ethanol series into 1PBS (pH 7.4), quenched with 5% H 2 O 2 in PBS for 5 min, pretreated with 0.1% trypsin for 15 min (5 min for embryonic tissues) and 0.1 M glycine for 1 min, blocked by 5% powdered milk for 10 min, 0.1% ovalbumin for 10 min, and 5% goat serum for 30 min, and then incubated with the primary antibody overnight, 4C, at a dilution of 1:250 (for negative control, 5% goat serum was used instead of primary antibody in this step). Sections were incubated with biotinylated goat anti-rabbit IgG and streptavidin-horseradish peroxidase (Amersham RPN 1231). Immunostaining was visualized using diaminobenzidine as a substrate. Counterstaining was performed using fast green or methyl green.
Results

Mepe expression during long bone development
Long bones, including the humeri and tibias, form through endochondral ossification. We first analyzed fetal skeletal elements for evidence of Mepe expression and found that although the primary ossification center formed and osteoblasts appeared by e15, we did not detect Mepe immunoreactivity until 2 days postnatal (data not shown and Fig. 1 ). At 2 days postnatal, weak Mepe immunostaining was detectable in the osteoblasts lining, the calcified cartilage cores in primary metaphyseal bone, and in osteocytes embedded in cortical bone matrix ( Fig. 1A-F ). Although Mepe immunoreactivity was not found in the extracellular matrix surrounding osteoblasts, the protein was detected on the wall of osteocyte lacunae.
In 12-week-old mice whose skeleton is mature, Mepe was detected in the osteocytes of cortical and trabecular bone ( Fig. 1G-I ). We found that the distribution of Mepe immunoreactivity within osteocytes of adult bone was comparable to its distribution during postnatal long bone development. Strong Mepe immunostaining was associated with both the cell body and the wall of osteocyte lacunae, suggesting that Mepe is secreted by osteocytes ( Fig. 1G-I ).
Mepe immunostaining was also noticeable in some hypertrophic and mature chondrocytes in the growth plates (data not shown) and in some bone marrow cells (Fig. 1C , E, I) of postnatal and adult mice. The immunopositive marrow cells exhibited the morphology of granulocytes and megakaryocytes. Further studies using specific markers would be required to determine the identity of the bone marrow cells expressing Mepe.
Mepe expression during non-stabilized tibia fracture healing Non-stabilized tibia fractures heal through endochondral ossification, during which a cartilage template is formed and replaced by bone (Colnot et al. 2003; Thompson et al. 2002) . By 3 days postfracture ( Fig. 2A-C) , which corresponds to the inflammatory phase of fracture healing, mesenchymal cells at the site of injury began to differentiate into either chondrocytes or osteoblasts (Le et al. 2001 ). This time point precedes proteoglycan staining. Alkaline phosphatase staining was detected in the periosteum and endosteum (Fig. 2B ), but not in the fracture site, suggesting that cells in the fracture site had not begun to deposit mineral. We did not detect Mepe immunostaining in the fracture callus at this time (Fig. 2C) .
At 6 days postfracture ( Fig. 2D-F) , which represents the soft callus phase of fracture healing, a large callus had formed and proteoglycan-positive cartilage was evident within the callus. The first evidence of new bone was noticed adjacent to the periosteum (Thompson et al. 2002) . Compared to 3 days postfracture, alkaline phosphatase activity was stronger in both the periosteum and the endosteum adjacent to the fracture site and around the cartilage islands, indicating bone cells had begun to deposit mineral in the callus (Fig. 2E) . Weak Mepe immunostaining was detectable in fibroblast-like cells within the callus (Fig. 2F) .
By 10 days postfracture ( Fig. 2G-J) , which corresponds to an early time point of the hard callus phase of fracture healing, a bulk of cartilage was seen throughout the callus. Alkaline phosphatase staining was robust in the cartilage callus, suggesting that the cartilage matrix was undergoing active mineralization. The cartilage callus underwent hypertrophy and new bone began to form around the cartilage islands and in the periosteal reaction area (Colnot et al. 2003) . Mepe immunostaining was detected within the late hypertrophic chondrocytes at the chondro-vascular junction (Fig. 2I) . Osteocytes embedded in the newly formed bone matrix presented intracellular Cartilage stained red. B, E, H, L, P Alkaline phosphatase (AP) staining (blue staining) on adjacent sections. C, F, I, M, Q Mepe immunostaining in area corresponding to solid red boxes in B, E, H, L, P, respectively. J, N, R Mepe immunostaining in area corresponding to the dashed red boxes in H, L, P, respectively. A At 3 days postfracture, SO/FG staining indicated no proteoglycan accumulation, as shown by the lack of red staining. B Minimal AP activity was evident on the endosteum (empty arrow) and periosteum (red arrow). C No Mepe immunostaining was detectable around the fracture site. D By 6 days, cartilage islands within the callus were visible by SO/FG staining (red arrow). E AP activity was seen around these cartilage islands (empty black arrow), in the periosteum (red arrows), and in the endosteum (empty red arrow). F Weak Mepe immunostaining was found in some of the cells within these cartilage islands (arrow). G By 10 days, abundant cartilage was present in the fracture callus. H AP activity was strong throughout the cartilage callus and in the new periosteal bone. I Mepe immunostaining was detectable in late hypertrophic chondrocytes within the callus (arrow). J Strong Mepe immunostaining was detected in osteocytes (arrows) embedded in the new bone. Mepe immunostaining was associated with the cell body and the cell processes. K By 14 days, the amount of cartilage within the callus was diminished. L AP activity was evident throughout the callus. M Mepe immunostaining was found in the pericellular matrix of late hypertrophic chondrocytes (arrows) at the ossification front. N Mepe immunostaining was localized in the osteocytes and in the lacunae (arrows) within the newly formed trabecular bone. Osteoblasts (arrowhead) lining the trabecular bone exhibited weak Mepe immunostaining. O By 28 days, the hypertrophic cartilage was completely resorbed and (P) AP activity was decreased. Q Strong Mepe immunostaining was seen in osteocytes in the new bone (arrows). R Osteoblasts (arrowheads) adjacent to trabecular bone and bone marrow cells (bm) were also positive for Mepe immunostaining. Scale bars A, B, D, E, G, H 0.5 mm; K, L, O, P 1 mm; Mepe 10 mm immunostaining. At this stage, the wall of osteocytes lacunae did not exhibit detectable Mepe immunoreactivity (Fig. 2J) .
By 14 days postfracture (Fig. 2K-N) , which corresponds to a later time point of the hard callus phase of fracture healing, the fracture callus was composed of hypertrophic cartilage, being actively replaced by bone. Alkaline phosphatase staining was detected throughout the callus, suggesting high activity of mineralization (Fig. 2L) . Mepe immunostaining was evident in the hypertrophic chondrocytes and their surrounding extracellular matrix at the ossification front (Fig. 2M) . Mepe immunoreactivity was also detected within osteoblasts and osteocytes in the new bone, with a stronger reactivity found in osteocytes (Fig. 2N) . Mepe immunostaining was now seen in the extracellular space around osteocytes, indicating that osteocytes had started to secrete the protein.
By 28 days postfracture (Fig. 2O-R) , during the remodeling phase of fracture healing, the callus was composed primarily of bone, which was undergoing extensive remodeling. Alkaline phosphatase activity was greatly diminished, showing a decrease in osteoblast activity and mineralization (Fig. 2P) . Mepe immunostaining was strong in osteocytes in the new bone and weak in the osteoblasts adjacent to trabecular bone (Fig. 2Q, R) .
Throughout the course of fracture repair, Mepe immunostaining in the mature osteocytes of the cortical bone and in bone marrow did not show any detectable changes compared to normal adult bone (Fig. 1 and data  not shown) . The results indicated that the injury and the healing process did not affect the basal level of Mepe expression in normal bone.
Mepe expression during repair of a cortical bone defect
Trichrome staining showed that a 1.0-mm cortical bone defect was filled with new bone by 10 days postsurgery. The new bone underwent remodeling and a new cortex was formed by 21 days (Fig. 3) . During this process, no cartilage was detected in the defect by safranin O/fast green staining (data not shown), demonstrating that this type of bone defect heals through intramembranous ossification, whereby mesenchymal cells differentiate directly into osteoblasts.
We found that by 5 days postsurgery, Mepe immunostaining was detectable in fibroblast-like cells within the defect (Fig. 3A, B) . By 10 days (Fig. 3C, D) , Mepe protein was detected in osteocytes within the new bone filling the defect. By 21 days (Fig. 3E, F) , strong Mepe expression was obvious in osteocytes of the newly formed cortex and in their surrounding lacunae.
Discussion
Mepe has recently been characterized as a novel bone metabolism regulator, however, its function is still poorly understood (Argiro et al. 2001; Gowen et al. 2003; Guo et al. 2002; MacDougall et al. 2002; Quarles 2003; Rowe et al. 2000) . To better understand the role of Mepe in bone formation, repair and remodeling, we carried out a detailed description of Mepe protein expression during long bone skeletogenesis, in normal adult bone, and during the process of tibia fracture and cortical defect repair.
Mepe in postnatal skeletogenesis and in adult bone
In this study, we used an immunohistochemical approach and found that Mepe protein was expressed during postnatal skeletogenesis. Mepe protein was first detected in osteocytes of mouse humeri by 2 days postnatal. These results indicated that during bone development, Mepe might not be involved in the initiation of ossification and mineralization that take place in late embryonic stages. Instead, Mepe could play a role during the late stage of bone growth and remodeling. Previous studies report the localization of Mepe mRNA in the rat mandible by e17 and sustained expression of Mepe at later time points (Igarashi et al. 2002) . The differences between those data and ours suggest that there might be a delay between Mepe mRNA expression and protein expression. Mepe protein might also be present at a very low level during late embryonic stages, which was undetectable by our immunostaining protocol. Another possibility is that there is a difference between the profile of Mepe expression in long bones, which form through endochondral ossification, and the mandible, which forms mainly through intramembranous ossification. Since the program of bone development is in large part recapitulated during bone healing, we addressed the possibility that Mepe also plays a role in bone healing. We examined cells at sites of skeletal injury, which heal through endochondral ossification (i.e., the non-stable tibia fracture), or through intramembranous ossification (i.e., a cortical defect injury).
Mepe in bone regeneration
Our analyses revealed that Mepe protein was not detected during the early stages of non-stabilized tibia fracture repair (3 days postfracture). Its expression in the cortex and the bone marrow adjacent to the fracture site was not significantly altered by injury. These findings suggest that Mepe may not take part in the inflammatory phase of fracture healing. Therefore, the presence of Mepe in bone marrow cells is probably not associated with a role in inflammation and bone physiology. During the soft callus (6-10 days postfracture), hard callus (14 days postfracture), and remodeling (28 days postfracture) phases, expression of Mepe was detectable within late hypertrophic chondrocytes, osteoblasts, and osteocytes in the callus, with a strong immunostaining found only in osteocytes. The detection of Mepe protein in osteoblasts is a novel finding since Mepe expression was previously reported in osteoblasts, but only at the RNA level (Igarashi et al. 2002) . The intensity of the immunostaining found in osteoblasts was weak compared to osteocytes, suggesting a lower expression level of the protein in osteoblasts. The strong staining in osteocytes might also be explained by the secretion and accumulation of Mepe in the lacunae of the cells. The amount of Mepe protein in osteocytes increased in parallel with alkaline phosphatase activity during the hard callus phase. These observations are consistent with a role of Mepe in late stages of osteoblast differentiation and in bone mineralization (Argiro et al. 2001; Igarashi et al. 2002; Petersen et al. 2000) .
During the remodeling phase of tibia fracture healing, the amount of Mepe protein did not attenuate along with the diminished activity of alkaline phosphatase. The expression pattern of Mepe protein during the healing of a tibial cortical defect was similar to that observed during non-stabilized fracture repair, with increased immunoreactivity toward the late stages of healing. These findings reinforce the role of Mepe as a negative regulator of bone mineralization (Gowen et al. 2003) . Mepe may play an adjunct role in mineralization, along with other major factors such as parathyroid hormone (PTH), calcitonin, and vitamin D (Boden and Kaplan 1990; Doppelt 1984; Tam et al. 1986; Wallach et al. 1999 ). This conclusion is further supported by the phenotype analysis of Mepe / mutant mice. The bone abnormality in Mepe / mutant mice is relatively subtle as compared to the severe bone diseases caused by hyperparathyroidism and deficiency of vitamin D (Doppelt 1984; Gowen et al. 2003) . However, the expression of Mepe in a variety of cells (including osteocytes, osteoblasts, bone marrow cells, chondrocytes in the growth plate, and brain cells; Rowe et al. 2000) suggests that Mepe may act on bone cells not only through an autocrine and paracrine manner, but also through endocrine mechanisms. Another possibility is that Mepe may have multiple functions and may also directly regulate renal phosphate excretion.
Taken together, our results show that Mepe is expressed during long bone skeletogenesis and regeneration. Further gain or loss of function experiments may elucidate the exact action of Mepe during bone mineralization. Mepe or its derivatives may turn out to be novel targets for the treatment of abnormal phosphate metabolism or bone healing.
